We are excited to announce that Sqilline Health’s Danny Platform has officially been selected as a Data Source for Real-World Data and Studies by the European Medicines Agency (EMA), marking a significant advancement in our commitment to enhancing healthcare research.
The development of the “HMA-EMA Catalogues of real-world data sources and studies” ( https://catalogues.ema.europa.eu/ ) represents a pivotal achievement, offering a vital platform for accessing essential metadata. These catalogues aid regulators, pharmaceutical companies, and researchers in accessing and utilizing real-world data for investigating the safety and efficacy of medicines.
Danny Platform functions as an analytics engine, aggregating and harmonizing heterogeneous data from leading hospitals, national registries, and other sources across Slovenia, Serbia, Romania, Croatia, and Bulgaria. It processes over 300 million health records for secondary data usage, including data from public sources.
Benefits for researchers, regulators, and pharmaceutical companies include:
- Facilitating discoverability of data sources for regulatory purposes
- Aiding in the assessment of data source suitability
- Improving interoperability between studies and data sources
- Enhancing transparency in real-world data utilization
For Sqilline Health, this recognition not only enhances decision-making for stakeholders and offers opportunities for high-impact publications and collaborative research projects but also improves interoperability and facilitates collaboration with world-class experts in Real-World Evidence generation.
